Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay - PubMed (original) (raw)
Comparative Study
Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay
A V Herz et al. Proc Natl Acad Sci U S A. 1996.
Abstract
Anti-viral drug treatment of human immunodeficiency virus type I (HIV-1) and hepatitis B virus (HBV) infections causes rapid reduction in plasma virus load. Viral decline occurs in several phases and provides information on important kinetic constants of virus replication in vivo and pharmacodynamical properties. We develop a mathematical model that takes into account the intracellular phase of the viral life-cycle, defined as the time between infection of a cell and production of new virus particles. We derive analytic solutions for the dynamics following treatment with reverse transcriptase inhibitors, protease inhibitors, or a combination of both. For HIV-1, our results show that the phase of rapid decay in plasma virus (days 2-7) allows precise estimates for the turnover rate of productively infected cells. The initial quasi-stationary phase (days 0-1) and the transition phase (days 1-2) are explained by the combined effects of pharmacological and intracellular delays, the clearance of free virus particles, and the decay of infected cells. Reliable estimates of the first three quantities are not possible from data on virus load only; such estimates require additional measurements. In contrast with HIV-1, for HBV our model predicts that frequent early sampling of plasma virus will lead to reliable estimates of the free virus half-life and the pharmacological properties of the administered drug. On the other hand, for HBV the half-life of infected cells cannot be estimated from plasma virus decay.
Similar articles
- Viral dynamics in hepatitis B virus infection.
Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Nowak MA, et al. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402. doi: 10.1073/pnas.93.9.4398. Proc Natl Acad Sci U S A. 1996. PMID: 8633078 Free PMC article. - Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters.
Nelson PW, Mittler JE, Perelson AS. Nelson PW, et al. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):405-12. doi: 10.1097/00126334-200104150-00002. J Acquir Immune Defic Syndr. 2001. PMID: 11391159 - HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. Perelson AS, et al. Science. 1996 Mar 15;271(5255):1582-6. doi: 10.1126/science.271.5255.1582. Science. 1996. PMID: 8599114 - [Reverse transcriptase inhibitors and the therapy of HIV infection].
Kraevskiĭ AA, Galegov GA. Kraevskiĭ AA, et al. Vestn Ross Akad Med Nauk. 1992;(11-12):3-6. Vestn Ross Akad Med Nauk. 1992. PMID: 1284219 Review. Russian. - Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
Vella S. Vella S. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S58-61. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 8595511 Review.
Cited by
- Modeling dynamics of acute HIV infection incorporating density-dependent cell death and multiplicity of infection.
Mainou E, Ribeiro RM, Conway JM. Mainou E, et al. PLoS Comput Biol. 2024 Jun 7;20(6):e1012129. doi: 10.1371/journal.pcbi.1012129. eCollection 2024 Jun. PLoS Comput Biol. 2024. PMID: 38848426 Free PMC article. - Incorporating Intracellular Processes in Virus Dynamics Models.
Ciupe SM, Conway JM. Ciupe SM, et al. Microorganisms. 2024 Apr 30;12(5):900. doi: 10.3390/microorganisms12050900. Microorganisms. 2024. PMID: 38792730 Free PMC article. Review. - Phenotypic flux: The role of physiology in explaining the conundrum of bacterial persistence amid phage attack.
Igler C. Igler C. Virus Evol. 2022 Sep 15;8(2):veac086. doi: 10.1093/ve/veac086. eCollection 2022. Virus Evol. 2022. PMID: 36225237 Free PMC article. Review. - Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.
Perelson AS, Ke R. Perelson AS, et al. Clin Pharmacol Ther. 2021 Apr;109(4):829-840. doi: 10.1002/cpt.2160. Epub 2021 Mar 8. Clin Pharmacol Ther. 2021. PMID: 33410134 Free PMC article. Review. - Incorporating age and delay into models for biophysical systems.
KhudaBukhsh WR, Kang HW, Kenah E, Rempała GA. KhudaBukhsh WR, et al. Phys Biol. 2021 Feb 13;18(1):015002. doi: 10.1088/1478-3975/abc2ab. Phys Biol. 2021. PMID: 33075757 Free PMC article.
References
- Science. 1996 Mar 15;271(5255):1582-6 - PubMed
- J Infect Dis. 1995 Jun;171(6):1411-9 - PubMed
- AIDS. 1995;9 Suppl A:S183-92 - PubMed
- Science. 1989 Mar 31;243(4899):1731-4 - PubMed
- J Theor Biol. 1991 Jul 7;151(1):1-40 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical